Ira Klein, MD, Discusses Quality Measures in Oncology
Ira Klein, MD, MBA, FACP, Chief Medical Officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology. Dr. Klein says that measurement is a driver for value and healthcare in the future. Quality measures like QOPI and HEDIS allow oncologists to measure how they should be rewarded and recognized for making improvement.
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
The group, led by Koch Institute director Tyler Jacks, used CRISPR to generate mutant genes that were then packaged into enteroviruses that were used to infect target organs in mice. This is a much faster process than the traditional method that need crossing genetically-engineered mice.
The study, published in Cell Stem Cell, identified a microRNA-mediated inhibitory pathway that repressed expression of the speech and language gene FOXP2, promoting metastases of breast cancer cells to distant sites.